Scott A. Frank
Research Subjects
Scott A. Frank has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Qiang Yang
Synthetic Molecule Design and Development, Lilly Research Laboratories
3 shared publications - Alison Campbell Brewer
Synthetic Molecule Design and Development, Lilly Research Laboratories
2 shared publications - Connor W. Coley
Massachusetts Institute of Technology
2 shared publications - Daniel J. Griffin
Pivotal & Commercial Synthetics, Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
2 shared publications Jing Chen
Shanghai SynTheAll Pharmaceutical R&D Co., Ltd. (STA), No. 90 Delin Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
2 shared publications- Joel R. Calvin
Eli Lilly and Company
2 shared publications
Latest Publications
- 30 June 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (7) , 1729-1730
Celebrating Lilly: 150 Years of Being a Medicine Company
- 30 June 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (7) , 1729-1730
Celebrating Lilly: 150 Years of Being a Medicine Company
- 13 May 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (6) , 1589-1601
Development of a Scalable Manufacturing Process for Kv1.3 Antagonist LY3972406 Hemiglutarate Hemihydrate
- 13 May 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (6) , 1589-1601
Development of a Scalable Manufacturing Process for Kv1.3 Antagonist LY3972406 Hemiglutarate Hemihydrate
- 1 April 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (4) , 1006-1018
Development of a Scalable Process for an IL-17A Inhibitor LY3509754. Part II: Synthesis of the α-Bromoketone Intermediate Leveraging Concomitant Decarboxylation Following Enzymatic Ester Hydrolysis
- 1 April 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (4) , 1006-1018
Development of a Scalable Process for an IL-17A Inhibitor LY3509754. Part II: Synthesis of the α-Bromoketone Intermediate Leveraging Concomitant Decarboxylation Following Enzymatic Ester Hydrolysis
- 27 March 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (4) , 1125-1135
Novel Baeyer–Villiger Oxidation of Nucleosides Applied to the Large-Scale Synthesis of MeMOP: A Key Amidite in the GalXC Platform
- 27 March 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (4) , 1125-1135
Novel Baeyer–Villiger Oxidation of Nucleosides Applied to the Large-Scale Synthesis of MeMOP: A Key Amidite in the GalXC Platform
- 5 July 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (7) , 2794-2805
Safety Guided Process Development and Scale-Up of the Highly Energetic Compound 4-Methyl-1,2,5-oxadiazole-3-carboxylic Acid
- 5 July 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (7) , 2794-2805
Safety Guided Process Development and Scale-Up of the Highly Energetic Compound 4-Methyl-1,2,5-oxadiazole-3-carboxylic Acid
- 28 May 2024
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 37 (6) , 1011-1022
Quantum Mechanical Assessment of Nitrosamine Potency
Nitrosamines are in the cohort of concern (CoC) as determined by regulatory guidance. CoC compounds are considered highly potent carcinogens that need to be limited below the threshold of toxicological concern, 1.5 μg/day. Nitrosamines like NDMA and NDEA require strict control, while novel nitrosamine drug substance-related impurities (NDSRIs) may or may not be characterized as potent carcinogens. A risk assessment based on the structural features of NDSRIs is important in order to predict potency because they lack substance-specific carcinogenicity. Herein, we present a quantum mechanical (QM)-based analysis on structurally diverse sets of nitrosamines to better understand how structure influences the reactivity that could result in carcinogenicity. We describe the potency trend through activation energies corresponding to α-hydroxylation, aldehyde formation, diazonium intermediate formation, reaction with DNA base, and hydrolysis reactions, and other probable metabolic pathways associated with the carcinogenicity of nitrosamines. We evaluated activation energies for selected cases such as N-nitroso pyrrolidines, N-nitroso piperidines, N-nitroso piperazines, N-nitroso morpholines, N-nitroso thiomorpholine, N-methyl nitroso aromatic, fluorine-substituted nitrosamines, and substituted aliphatic nitrosamines. We compare these results to the recent framework of the carcinogenic potency characterization approach (CPCA) proposed by health authorities which is meant to give guidance on acceptable intakes (AI) for NDSRIs lacking substance-specific carcinogenicity data. We show examples where QM modeling and CPCA are aligned and examples where CPCA both underestimates and overestimates the AI. In cases where CPCA predicts high potency for NDSRIs, QM modeling can help better estimate an AI. Our results suggest that a combined mechanistic understanding of α-hydroxylation, aldehyde formation, hydrolysis, and reaction with DNA bases could help identify the structural features that underpin the potency of nitrosamines. We anticipate this work will be a valuable addition to the CPCA and provide a more analytical way to estimate AI for novel NDSRIs.
- 28 May 2024
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 37 (6) , 1011-1022
Quantum Mechanical Assessment of Nitrosamine Potency
Nitrosamines are in the cohort of concern (CoC) as determined by regulatory guidance. CoC compounds are considered highly potent carcinogens that need to be limited below the threshold of toxicological concern, 1.5 μg/day. Nitrosamines like NDMA and NDEA require strict control, while novel nitrosamine drug substance-related impurities (NDSRIs) may or may not be characterized as potent carcinogens. A risk assessment based on the structural features of NDSRIs is important in order to predict potency because they lack substance-specific carcinogenicity. Herein, we present a quantum mechanical (QM)-based analysis on structurally diverse sets of nitrosamines to better understand how structure influences the reactivity that could result in carcinogenicity. We describe the potency trend through activation energies corresponding to α-hydroxylation, aldehyde formation, diazonium intermediate formation, reaction with DNA base, and hydrolysis reactions, and other probable metabolic pathways associated with the carcinogenicity of nitrosamines. We evaluated activation energies for selected cases such as N-nitroso pyrrolidines, N-nitroso piperidines, N-nitroso piperazines, N-nitroso morpholines, N-nitroso thiomorpholine, N-methyl nitroso aromatic, fluorine-substituted nitrosamines, and substituted aliphatic nitrosamines. We compare these results to the recent framework of the carcinogenic potency characterization approach (CPCA) proposed by health authorities which is meant to give guidance on acceptable intakes (AI) for NDSRIs lacking substance-specific carcinogenicity data. We show examples where QM modeling and CPCA are aligned and examples where CPCA both underestimates and overestimates the AI. In cases where CPCA predicts high potency for NDSRIs, QM modeling can help better estimate an AI. Our results suggest that a combined mechanistic understanding of α-hydroxylation, aldehyde formation, hydrolysis, and reaction with DNA bases could help identify the structural features that underpin the potency of nitrosamines. We anticipate this work will be a valuable addition to the CPCA and provide a more analytical way to estimate AI for novel NDSRIs.
- Open Access
- 25 September 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (11) , 1868-1879
Opportunities for Machine Learning and Artificial Intelligence to Advance Synthetic Drug Substance Process Development
- 25 September 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (11) , 1868-1879
Open AccessOpportunities for Machine Learning and Artificial Intelligence to Advance Synthetic Drug Substance Process Development
- Open Access
- 31 May 2023
- Published by Swiss Chemical Society in Chimia
- Vol. 77 (5) , 319
The History of Flow Chemistry at Eli Lilly and Company
Flow chemistry was initially used for speed to early phase material delivery in the development laboratories, scaling up chemical transformations that we would not or could not scale up batch for safety reasons. Some early examples included a Newman Kwart Rearrangement, Claisen rearrangement, hydroformylation, and thermal imidazole cyclization. Next, flow chemistry was used to enable safe scale up of hazardous chemistries to manufacturing plants. Examples included high pressure hydrogenation, aerobic oxidation, and Grignard formation reactions. More recently, flow chemistry was used in Small Volume Continuous (SVC) processes, where highly potent oncolytic molecules were produced by fully continuous processes at about 10 kg/day including reaction, extraction, distillation, and crystallization, using disposable equipment contained in fume hoods.
- 31 May 2023
- Published by Swiss Chemical Society in Chimia
- Vol. 77 (5) , 319
Open AccessThe History of Flow Chemistry at Eli Lilly and Company
Flow chemistry was initially used for speed to early phase material delivery in the development laboratories, scaling up chemical transformations that we would not or could not scale up batch for safety reasons. Some early examples included a Newman Kwart Rearrangement, Claisen rearrangement, hydroformylation, and thermal imidazole cyclization. Next, flow chemistry was used to enable safe scale up of hazardous chemistries to manufacturing plants. Examples included high pressure hydrogenation, aerobic oxidation, and Grignard formation reactions. More recently, flow chemistry was used in Small Volume Continuous (SVC) processes, where highly potent oncolytic molecules were produced by fully continuous processes at about 10 kg/day including reaction, extraction, distillation, and crystallization, using disposable equipment contained in fume hoods.
- 7 October 2021
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 60 (46) , 24573-24581
Tunable and Cooperative Catalysis for Enantioselective Pictet‐Spengler Reaction with Varied Nitrogen‐Containing Heterocyclic Carboxaldehydes
Herein we report an organocatalytic enantioselective functionalization of heterocyclic carboxaldehydes via the Pictet–Spengler reaction. Through careful pairing of novel squaramide and Brønsted acid catalysts, our method tolerates a breadth of heterocycles, enabling preparation of a series of heterocycle conjugated β‐(tetrahydro)carbolines in good yield and enantioselectivity. Careful selection of carboxylic acid co‐catalyst is essential for toleration of a variety of regioisomeric heterocycles. Utility is demonstrated via the three‐step stereoselective preparation of pyridine‐containing analogues of potent selective estrogen receptor downregulator and U.S. FDA approved drug Tadalafil.
- 7 October 2021
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 60 (46) , 24573-24581
Tunable and Cooperative Catalysis for Enantioselective Pictet‐Spengler Reaction with Varied Nitrogen‐Containing Heterocyclic Carboxaldehydes
Herein we report an organocatalytic enantioselective functionalization of heterocyclic carboxaldehydes via the Pictet–Spengler reaction. Through careful pairing of novel squaramide and Brønsted acid catalysts, our method tolerates a breadth of heterocycles, enabling preparation of a series of heterocycle conjugated β‐(tetrahydro)carbolines in good yield and enantioselectivity. Careful selection of carboxylic acid co‐catalyst is essential for toleration of a variety of regioisomeric heterocycles. Utility is demonstrated via the three‐step stereoselective preparation of pyridine‐containing analogues of potent selective estrogen receptor downregulator and U.S. FDA approved drug Tadalafil.
- 6 September 2021
- Published by Wiley in Angewandte Chemie
- Vol. 133 (46) , 24778-24786
Tunable and Cooperative Catalysis for Enantioselective Pictet‐Spengler Reaction with Varied Nitrogen‐Containing Heterocyclic Carboxaldehydes
Herein we report an organocatalytic enantioselective functionalization of heterocyclic carboxaldehydes via the Pictet–Spengler reaction. Through careful pairing of novel squaramide and Brønsted acid catalysts, our method tolerates a breadth of heterocycles, enabling preparation of a series of heterocycle conjugated β‐(tetrahydro)carbolines in good yield and enantioselectivity. Careful selection of carboxylic acid co‐catalyst is essential for toleration of a variety of regioisomeric heterocycles. Utility is demonstrated via the three‐step stereoselective preparation of pyridine‐containing analogues of potent selective estrogen receptor downregulator and U.S. FDA approved drug Tadalafil.
- 6 September 2021
- Published by Wiley in Angewandte Chemie
- Vol. 133 (46) , 24778-24786
Tunable and Cooperative Catalysis for Enantioselective Pictet‐Spengler Reaction with Varied Nitrogen‐Containing Heterocyclic Carboxaldehydes
Herein we report an organocatalytic enantioselective functionalization of heterocyclic carboxaldehydes via the Pictet–Spengler reaction. Through careful pairing of novel squaramide and Brønsted acid catalysts, our method tolerates a breadth of heterocycles, enabling preparation of a series of heterocycle conjugated β‐(tetrahydro)carbolines in good yield and enantioselectivity. Careful selection of carboxylic acid co‐catalyst is essential for toleration of a variety of regioisomeric heterocycles. Utility is demonstrated via the three‐step stereoselective preparation of pyridine‐containing analogues of potent selective estrogen receptor downregulator and U.S. FDA approved drug Tadalafil.